Methylation of TMS1/ASC Gene in Prostate Cancer
Author Information
Author(s): Das Partha M, Ramachandran Kavitha, VanWert Jane, Ferdinand Larry, Gopisetty Gopal, Reis Isildinha M, Singal Rakesh
Primary Institution: Sylvester Comprehensive Cancer Center, University of Miami
Hypothesis
The study examines the role of TMS1/ASC gene methylation in prostate cancer and its correlation with race and clinico-pathological features.
Conclusion
Methylation-mediated silencing of TMS1/ASC is common in prostate cancer, suggesting it could be a diagnostic and prognostic marker.
Supporting Evidence
- TMS1/ASC gene methylation was found in 63.6% of prostate cancer cases compared to 35.3% in benign prostatic hyperplasia.
- The odds ratio for TMS1/ASC methylation in White patients was 7.6, indicating a significant association with prostate cancer.
- Methylation of TMS1/ASC was more prevalent in prostate cancer cases than controls in White patients.
Takeaway
The study found that a gene important for cell death is often turned off in prostate cancer due to a chemical change, and this might be different for different races.
Methodology
The study used RT-PCR, MS-PCR, and ChIP assays to analyze gene expression and methylation in prostate cancer cell lines and tissue samples.
Potential Biases
Potential bias due to the racial distribution of the sample and the limited number of participants from different ethnic backgrounds.
Limitations
The study's sample size was limited to 66 prostate cancer patients and 34 benign prostatic hyperplasia controls, which may affect the generalizability of the findings.
Participant Demographics
Participants included 66 prostate cancer patients and 34 benign prostatic hyperplasia controls, with a racial distribution of 31.8% Black and 68.2% White.
Statistical Information
P-Value
0.002
Confidence Interval
95% CI 1.4 – 9.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website